Skip to content

Neointimal Features in Patients With Restenosis of Calcified Lesions

Characteristics of Intimal and Neoatherosclerosis in Patients With Restenosis After DES Implantation for Calcified Lesions

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05451368
Enrollment
120
Registered
2022-07-11
Start date
2022-03-17
Completion date
2023-03-31
Last updated
2022-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Calcification, Neoatherosclerosis, Neointima, Restenosis

Keywords

coronary artery calcification, ISR, neoatherosclerosis

Brief summary

Previous studies have suggested that restenosis (RS) after stenting is mainly due to smooth muscle cell proliferation and migration, but recent evidence suggests that in-stent restenosis(ISR) is associated with a number of factors. Coronary artery calcification is an independent predictor of ischaemia-mediated revascularisation 1 year after percutaneous coronary intervention (PCI) following RS.The characteristics of new neointima in patients with in-stent restenosis of calcified lesions are important issues to explore

Detailed description

The characteristics of the endothelium after DES following implantation of calcified lesions have always been of interest to us. Its inherent peculiarities make the new endothelium of calcified lesions different. Firstly, the presence of calcification makes the neointima heal slowly. In addition DES has an anti-proliferative effect, which further diminishes the healing ability of the neointima of calcified lesions and impairs the barrier function of the endothelium. This may have a similar pathway to the formation of neointimal atherosclerosis or heterogeneous endothelium within the neointima. Secondly, stents with calcified lesions can be accompanied by incomplete stent expansion, stent fracture and stent misalignment. These conditions may accelerate the occurrence of restenosis within the stent. Thirdly, there are different types of calcified lesions. Different types of calcified lesions may heal and restenosis in different ways. It is therefore understood that calcified lesion healing has a number of pathways that exist in contradiction. These are issues that need to be explored in depth.

Interventions

OTHERCoronary artery calcification lesions

Calcification of atherosclerosis, a complex, organic, regulated and active process, is one of the manifestations of atherosclerosis. The progression of coronary atherosclerosis is a strong independent predictor of future coronary events. It has been shown that coronary artery calcification affects the healing of the neointima and the function of the endothelium after stenting. This may lead to changes in neointimal morphology and the development of neoatherosclerosis after stent implantation.

Sponsors

Shenyang Northern Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. The patient is older than 18 years. 2. The patient had undergone coronary angiography at our hospital for PCI and had first ISR with drug-eluting stent implantation. 3. Calcified lesion greater than 5 mm in length. 4. Stent implantation time greater than 30 days.

Exclusion criteria

1. Bridge vessel lesions following coronary artery bypass grafting. 2. Planned modification of the DAPT regimen for medical reasons or other surgical procedures requiring modification within 3 months of the index procedure. 3. Patients undergoing heart transplantation. 4. Significant angiogenic lesions in the target vessel that may prevent stent delivery and deployment. 5. Bifurcation disease lesions involving collateral branches ≥ 2.5 mm in diameter. 6. Lesions deemed by the investigator to be unsuitable for OCT imaging (e.g., extremely curved, very distal lesions). 7. Serum creatinine \> 2.0 mg/dl at the time of treatment. 8. Greater than three types of stent implantation. 9. Subjects with malignancy or other co-morbidities (i.e., severe liver, kidney, lung, or pancreatic disease with a life expectancy of less than 18 months or which may result in protocol non-compliance).

Design outcomes

Primary

MeasureTime frameDescription
Mean lumen areathrough study completion, an average of 1 yearQuantitative Indicators,the mean area bounded by the luminal border on OCT(Optical Coherence Tomography)
Minimum lumen areathrough study completion, an average of 1 yearQuantitative Indicators,the minimum area bounded by the luminal border on OCT
Maximum lumen areathrough study completion, an average of 1 yearQuantitative Indicators,the maximum area bounded by the luminal border on OCT
Percent area stenosisthrough study completion, an average of 1 yearQuantitative Indicators,the (reference lumen area minus the minimum lumen area) divided by the reference lumen area, multiplied by 100. The reference segment used should be specified (proximal, distal, largest or average) on OCT
Mean stent areathrough study completion, an average of 1 yearQuantitative Indicators,the mean area bounded by the stent border on OCT
Minimum stent areathrough study completion, an average of 1 yearQuantitative Indicators,the Minimum area bounded by the stent border on OCT
Maximum stent areathrough study completion, an average of 1 yearQuantitative Indicators,the Maximum area bounded by the stent border on OCT
lipid-laden intimathrough study completion, an average of 1 yearQualitative indicators,a diffusely bordered, signal-poor region with overlying signal-rich bands in the intima on OCT.the investigators measured its incidence on OCT.
Calcificationthrough study completion, an average of 1 yearQualitative indicators,shows a well-delineated, signal-poor region with sharp borders.the investigators measured its incidence on OCT.
Thrombithrough study completion, an average of 1 yearQualitative indicators,masses protruding into the lumen and discontinuous from the surface of the vessel wall.the investigators measured its incidence on OCT.
Intimal rupturethrough study completion, an average of 1 yearQualitative indicators,discontinuity of the fibrous cap connecting the lumen.the investigators measured its incidence on OCT.
Neovascularizationthrough study completion, an average of 1 yearQualitative indicators,the presence of signal-poor holes or tubular structures with a diameter of 50 to 300 μm that are not connected to the vessel lumen.the investigators measured its incidence on OCT.
Thin-cap fibroatheroma (TCFA)through study completion, an average of 1 yearcontaining intima was defined as fibrous cap thickness ≤65 μm at the thinnest segment and an angle of lipid tissue ≥180°.the investigators measured its incidence on OCT.
Macrophage infiltrationthrough study completion, an average of 1 yearQualitative indicators,a bright spot with a high signal variance from the surrounding tissue.the investigators measured its incidence on OCT.
Stent underexpansionthrough study completion, an average of 1 yearQualitative indicators,Stent expansion describes the minimum stent cross-sectional area either as an absolute measure (absolute expansion), or compared with the predefined reference area, which can be the proximal, distal, largest, or average reference area (relative expansion).the investigators measured its incidence on OCT.
stent fracturethrough study completion, an average of 1 yearQualitative indicators,the interruption of stent continuity.the investigators measured its incidence on OCT.
Uncovered strutsthrough study completion, an average of 1 yearthe ratio of uncovered-to-total stent struts per section was calculated and expressed as percent on OCT.
neoatherosclerosisthrough study completion, an average of 1 yearneoatherosclerosis were defined by the presence of one or more of the following: lipid laden tissue ,thin-cap fibroatheroma (TCFA),neointimal calcification,Macrophage infiltration.the investigators measured its incidence .

Countries

China

Contacts

Primary Contactgeng wang, M.D.
wanggeng69@163.com13309886393

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026